Case Study – Ontario Group of Hospitals
Ontario-based hospitals use a custom Hereditary Cancer Solution by SOPHiA GENETiCS™ for Provincial Hereditary Cancer Testing
Country
Canada
Research Challenge
Custom future-proof gene list, cost and time effective workflow
Solution
SOPHiA DDM™ Comprehensive Hereditary Cancer Solution & SOPHiA DDM™ Set-Up Program
- Fulfil the updated Ontario guidelines
- Keep testing in-house
- Utilize a user-friendly secondary and tertiary analysis platform
- Maximize efficiency of their laboratory workflows
Both hospitals required an optimal solution that could effectively meet their needs, as well as those of the local governing body. The teams were aware of the financial, logistical, and technical challenges associated with adopting a custom panel.
References
1. Ontario Health. Cancer Care Ontario. Hereditary Cancer Testing Eligibility Criteria: Version 3. 1 October 2022.
Disclaimer: The SOPHiA DDM™ Comprehensive Hereditary Cancer Solution is for Research Use Only and not for use in diagnostic procedures. The information in this presentation is about a product that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence. SOPHIA GENETICS™ does not accept any liability for products, for clinical, diagnostic or other use that have been self-validated by third parties.
Learn more about how these Ontario-based Hospitals adopted a customized SOPHiA DDM™ Comprehensive Hereditary Cancer solution for their Laboratories.
Related Products
SOPHiA GENETICS Hereditary Cancer Solutions
Confidently assess genetic variants predisposing to cancer
Related Case Studies
Genomic Diagnostics, Australia
Genomic Diagnostics improve equity of access to hereditary cancer genomic analysis in Australia with the SOPHiA DDM™ Hereditary Cancer Solution v1.1.
TomaLab Advanced Biomedical Assays
A Clinical Case Study about the value of the SOPHiA DDM™ HRD Dx Solution in clinical routine
The Andalusian Health Service use the CE IVD-marked SOPHiA DDM™️ Dx Hereditary Cancer Solution to detect an Alu insertion (Clinical Decision Support Only) in an ovarian cancer case
The SOPHiA DDM™️ Platform enables the quick and confident assessment of ~1000 hereditary cancer samples per year.
The Andalusian Health Service address a colorectal cancer case with the CE IVD-marked SOPHiA DDM™️ Dx Hereditary Cancer Solution
The CNV detection algorithm in SOPHiA DDM™️ efficiently identified a complex duplication in MSH2.
The Andalusian Health Service conduct trio analysis with the SOPHiA DDM™ Platform to identify the underlying cause of 2 neonatal deaths
The SOPHiA DDM Platform was a very useful tool for resolving this complex case.
Motol University Hospital in Prague discover a novel cause of inherited cardiac disease with the SOPHiA Clinical Exome Solution v3
The laboratory finds the community frequency tool very useful for making quick decisions about whether to deeply investigate a variant.
Collaborating with the Bambino Gesù Children’s Hospital to develop the SOPHiA Nephropathies Solution
SOPHiA DDM™ enables the laboratory to process a large number of samples in a simple way to gain exhaustive insights.
DASA leverages on the SOPHiA GENETICS multimodal approach in the fight against cancer
SOPHiA GENETICS is Dasa’s partner of choice for data-driven medicine utilizing a multimodal data approach and SOPHiA DDM Trial Match.
Indian research hospital chose SOPHiA DDM™ for the analysis of gene fusion events
SOPHiA DDM™’s unique community frequency tool helps to assess solid tumor variant frequency in the hospital’s cohort and globally.
University of Sassari adopts SOPHiA DDM™ for SARS-CoV-2 research and surveillance
SOPHiA DDM™ saves the reference center a massive amount of data analysis time so they can focus more on interpretation.